Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil and Estramustine in Advanced Prostate Cancer
NCT00132756Phase 2Terminated
- Sponsor
- Morton Plant Mease Health Care
- Start
- Dec 2003
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pegylated liposomal doxorubicin and estramustine in prostate cancer (PCa), sponsored by Morton Plant Mease Health Care. Primary endpoint: Reduction of measurable disease or PSA level by at least 50%. Started Dec 2003; status: terminated.
02
Drugs
pegylated liposomal doxorubicinestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00132756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132756.